As of 30 Sep 2025, 5 institutional investors reported holding 11,162 shares of CIDARA THERAPEUTICS INC COM NEW - Stock (CDTX).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 11,162 | $1,068,585 | +$479,120 | $95.76 | 5 |
| 2025 Q2 | 6,156 | $299,872 | +$299,872 | $55.36 | 2 |
| 2024 Q3 | 0 | $0 | -$3,680 | $95.76 | 0 |
| 2024 Q2 | 4,000 | $3,680 | -$210,710 | $0.92 | 1 |
| 2024 Q1 | 234,568 | $213,597 | -$1,392,613 | $0.92 | 7 |
| 2023 Q4 | 23,179,993 | $18,404,978 | -$664,259 | $0.79 | 50 |
| 2023 Q3 | 24,074,750 | $22,682,521 | -$2,155,070 | $0.94 | 52 |
| 2023 Q2 | 26,255,377 | $29,668,820 | -$1,146,488 | $1.13 | 52 |
| 2023 Q1 | 27,108,727 | $34,423,224 | +$1,370,925 | $1.27 | 52 |
| 2022 Q4 | 26,634,589 | $20,139,425 | -$163,220 | $0.76 | 39 |
| 2022 Q3 | 27,071,246 | $17,059,222 | -$37,048 | $0.63 | 38 |
| 2022 Q2 | 27,212,375 | $13,293,172 | -$1,659,086 | $0.49 | 40 |
| 2022 Q1 | 30,310,443 | $25,234,294 | -$985,113 | $0.83 | 39 |
| 2021 Q4 | 31,078,404 | $39,465,681 | +$12,358,241 | $1.27 | 48 |
| 2021 Q3 | 18,444,750 | $41,310,590 | -$3,104,500 | $2.24 | 48 |
| 2021 Q2 | 20,045,479 | $40,489,347 | -$3,281,186 | $2.02 | 53 |
| 2021 Q1 | 21,295,412 | $56,644,120 | -$5,974,915 | $2.66 | 62 |
| 2020 Q4 | 24,040,576 | $48,079,100 | -$6,739,988 | $2.00 | 61 |
| 2020 Q3 | 24,088,481 | $68,671,126 | +$1,308,655 | $2.85 | 64 |
| 2020 Q2 | 25,106,069 | $92,697,628 | +$12,126,390 | $3.69 | 64 |
| 2020 Q1 | 22,439,168 | $55,624,774 | +$14,474,491 | $2.48 | 51 |
| 2019 Q4 | 16,488,827 | $63,314,008 | +$3,476,604 | $3.84 | 50 |
| 2019 Q3 | 14,467,279 | $28,864,006 | -$2,401,329 | $2.00 | 34 |
| 2019 Q2 | 15,822,310 | $26,542,005 | +$2,152,321 | $1.68 | 41 |
| 2019 Q1 | 16,070,639 | $42,548,008 | -$4,202,865 | $2.65 | 49 |
| 2018 Q4 | 17,674,910 | $41,473,007 | -$4,944,712 | $2.35 | 49 |
| 2018 Q3 | 17,262,263 | $73,861,129 | -$2,219,933 | $4.40 | 59 |
| 2018 Q2 | 17,747,231 | $89,784,168 | +$21,171,828 | $5.20 | 56 |
| 2018 Q1 | 13,263,019 | $53,050,012 | -$8,594,243 | $4.00 | 58 |
| 2017 Q4 | 14,927,264 | $101,509,020 | +$13,533,641 | $6.80 | 47 |
| 2017 Q3 | 11,198,249 | $90,704,024 | +$922,700 | $8.10 | 40 |
| 2017 Q2 | 11,125,500 | $83,440,023 | -$1,713,668 | $7.50 | 53 |
| 2017 Q1 | 11,448,903 | $89,297,484 | +$3,844,548 | $7.80 | 51 |
| 2016 Q4 | 11,394,722 | $118,506,278 | +$22,410,751 | $10.40 | 57 |
| 2016 Q3 | 7,878,814 | $90,208,154 | -$2,740,366 | $11.45 | 51 |
| 2016 Q2 | 8,168,686 | $84,214,036 | -$7,110,017 | $10.31 | 55 |
| 2016 Q1 | 8,816,189 | $111,962,000 | -$1,557,200 | $12.70 | 42 |
| 2015 Q4 | 8,936,177 | $153,339,825 | +$3,278,563 | $17.16 | 43 |
| 2015 Q3 | 6,419,154 | $81,647,656 | +$7,049,997 | $12.72 | 44 |
| 2015 Q2 | 5,937,620 | $83,244,564 | +$67,243,627 | $14.02 | 43 |